Latest Astellas Pharma US Inc. Stories
CHICAGO, Oct. 27 /PRNewswire/ -- ReachMD XM 157 announces a new "Medical Industry Feature of the Week" highlighting a vasopressin receptor antagonist and its effects on management of euvolemic and hypervolemic hyponatremia in the hospital setting. ReachMD XM 157, the first and only network for medical professionals, will air the program "AVP Antagonists: Turning the Tide Against Hyponatremia" four times a day October 27-31, November 10-14, and January 5-8. Healthcare professionals can tune...
DEERFIELD, Ill., Oct. 22 /PRNewswire/ -- Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new premixed formulation of Vaprisol: Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients....
DEERFIELD, Ill., Oct. 14 /PRNewswire/ -- Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched in April 2008, the Astellas Ride of a Lifetime contest asked organ transplant recipients to write an essay explaining how their transplant experience transformed their life. The five winners of the contest will ride the Donate Life float in the 2009 Rose Parade -- one of the most celebrated...
VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. today announced that it has been informed by its co-development partner, Astellas Pharma US, Inc., that an End of Review meeting with the U.S. Food & Drug Administration (FDA) has been scheduled for November 14th, 2008 regarding the New Drug Application (NDA) for KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. At the conclusion of FDA's review of an application...
DEERFIELD, Ill., Oct. 1 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") is pleased to announce its partnership with the National Science Teachers Association (NSTA) to help further science education in the greater Chicago-area. Astellas will support 15 greater Chicago-area science teachers to participate in the 2008 NSTA New Science Teacher Academy, a national, year-long program that connects new science teachers to a range of tools and resources, while providing the essential support...
To: SCIENCE EDITORS Contact: Kate Meyer of the National Science Teachers Association, +1-703-312-9211, kmeyer@nsta.org 185 Early-Career Science Teachers From Across the Country to Begin Year-long Professional Development Program ARLINGTON, Va., Sept. 10 /PRNewswire-USNewswire/ --The National Science Teachers Association (NSTA), the largest professional organization in the world promoting excellence and innovation in science teaching and learning, in partnership with the Amgen Foundation;...
To: HEALTH EDITORS Contact: Kate Meyer of National Science Teachers Association, +1- 703- 312-9211, kmeyer@nsta.org ARLINGTON, Va., Aug. 27 /PRNewswire-USNewswire/ -- The National Science Teachers Association (NSTA), the largest professional organization in the world promoting excellence and innovation in science teaching and learning, today announced the expansion of the NSTA New Science Teacher Academy, co- founded by the Amgen Foundation. Three leading organizations, committed to...
VANCOUVER and DEERFIELD, IL, Aug. 11 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced that they have received an action letter dated August 8, 2008 from the U.S. Food and Drug Administration (FDA) for KYNAPID(TM) (vernakalant hydrochloride) Injection for the treatment of atrial fibrillation (AF) - a potentially life-threatening condition that occurs when electrical signals in the heart malfunction. KYNAPID...
DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide MPI -- a test that detects and characterizes coronary artery disease -- in patients unable to undergo adequate exercise stress. Lexiscan, co-developed with CV Therapeutics , is the first A2A adenosine receptor agonist shown to be safe and effective as a...
